We are aware of the limitations of our study, mostly, the small sample size, but we believe that despite of this, our results must be explored in future clinical trials, as we showed that the evaluation of the expression of RAD23B and TYMS associated with the evaluation of CTC kinetics may facilitate the personalized treatment of rectal cancer. The gene discussed is RAD23B; the disease is rectal cancer.